Evidence map›Paper›PMID 40430545›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews.

Sara Otero-Torres, Rosa Rodríguez-Mauriz, Eduard Fort-Casamartina, Ana Clopés-Estela, Francesc Soler-Rotllant, Sandra Fontanals-Martínez, Olalla Montero-Pérez

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sara Otero-TorresPharmacy Department, Catalan Institute of Oncology (ICO), Hospital Duran I Reynals, 08098 L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-8166-1163
Rosa Rodríguez-MaurizPharmacy Department, Catalan Institute of Oncology (ICO), Hospital Duran I Reynals, 08098 L'Hospitalet de Llobregat, Spain.ORCID 0000-0003-3019-3483
Eduard Fort-CasamartinaPharmacy Department, Catalan Institute of Oncology (ICO), Hospital Duran I Reynals, 08098 L'Hospitalet de Llobregat, Spain.ORCID 0009-0007-8391-202X
Ana Clopés-EstelaMedicines Department, Catalan Health Service (Catsalut), 08007 Barcelona, Spain.ORCID 0000-0002-1857-362X
Francesc Soler-RotllantPharmacy Department, Catalan Institute of Oncology (ICO), Hospital Duran I Reynals, 08098 L'Hospitalet de Llobregat, Spain.
Sandra Fontanals-MartínezPharmacy Department, Catalan Institute of Oncology (ICO), Hospital Duran I Reynals, 08098 L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-4450-2227
Olalla Montero-PérezPharmacy Department, Catalan Institute of Oncology (ICO), Hospital Duran I Reynals, 08098 L'Hospitalet de Llobregat, Spain.ORCID 0000-0002-2671-3354

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clinical oncologyDPYD genotypingfluoropyrimidinesystematic reviewtoxicity

Identifiers

PMID40430545
PMCPMC12115295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.